Found: 40
Select item for more details and to access through your institution.
In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome.
- Published in:
- EMBO Molecular Medicine, 2018, v. 10, n. 11, p. N.PAG, doi. 10.15252/emmm.201809158
- By:
- Publication type:
- Article
Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells.
- Published in:
- Life (2075-1729), 2021, v. 11, n. 4, p. 269, doi. 10.3390/life11040269
- By:
- Publication type:
- Article
CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
- Published in:
- Frontiers in Immunology, 2022, v. 12, p. 1, doi. 10.3389/fimmu.2021.798087
- By:
- Publication type:
- Article
3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids.
- Published in:
- EMBO Journal, 2019, v. 38, n. 12, p. 1, doi. 10.15252/embj.2018100928
- By:
- Publication type:
- Article
Recombinant derivatives of the human high-mobility group protein HMGB2 mediate efficient nonviral gene delivery.
- Published in:
- FEBS Journal, 2005, v. 272, n. 16, p. 4221, doi. 10.1111/j.1742-4658.2005.04834.x
- By:
- Publication type:
- Article
Vaccination Directed against the Human Endogenous Retrovirus-K Envelope Protein Inhibits Tumor Growth in a Murine Model System.
- Published in:
- PLoS ONE, 2013, v. 8, n. 8, p. 1, doi. 10.1371/journal.pone.0072756
- By:
- Publication type:
- Article
EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and Mediates Specific Killing of Tumor Cells.
- Published in:
- PLoS ONE, 2013, v. 8, n. 4, p. 1, doi. 10.1371/journal.pone.0061267
- By:
- Publication type:
- Article
Maltose-Binding Protein Enhances Secretion of Recombinant Human Granzyme B Accompanied by In Vivo Processing of a Precursor MBP Fusion Protein.
- Published in:
- PLoS ONE, 2010, v. 5, n. 12, p. 1, doi. 10.1371/journal.pone.0014404
- By:
- Publication type:
- Article
Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2905, doi. 10.1007/s00262-023-03374-x
- By:
- Publication type:
- Article
Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 4, p. 513, doi. 10.1007/s00262-018-2119-y
- By:
- Publication type:
- Article
Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 1, p. 25, doi. 10.1007/s00262-017-2055-2
- By:
- Publication type:
- Article
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 3, p. 411, doi. 10.1007/s00262-007-0383-3
- By:
- Publication type:
- Article
High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
- Published in:
- Frontiers in Immunology, 2020, p. 1, doi. 10.3389/fimmu.2019.03123
- By:
- Publication type:
- Article
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
- Published in:
- Frontiers in Immunology, 2019, v. 10, p. 1, doi. 10.3389/fimmu.2019.02683
- By:
- Publication type:
- Article
Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD 2 -Targeted CAR-NK Cells and Mediates Potent Cell Killing in the Absence of IL-2.
- Published in:
- Cancers, 2023, v. 15, n. 17, p. 4310, doi. 10.3390/cancers15174310
- By:
- Publication type:
- Article
Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.
- Published in:
- Cancers, 2021, v. 13, n. 6, p. 1443, doi. 10.3390/cancers13061443
- By:
- Publication type:
- Article
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor.
- Published in:
- Molecular Therapy, 2015, v. 23, n. 2, p. 330, doi. 10.1038/mt.2014.219
- By:
- Publication type:
- Article
Selective Induction of Cancer Cell Death by Targeted Granzyme B.
- Published in:
- Antibodies (2073-4468), 2013, v. 2, n. 1, p. 130, doi. 10.3390/antib2010130
- By:
- Publication type:
- Article
Preclinical assessment of CARNK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1254821
- By:
- Publication type:
- Article
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1228894
- By:
- Publication type:
- Article
Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival.
- Published in:
- Neuro-Oncology, 2016, v. 18, n. 7, p. 974, doi. 10.1093/neuonc/nov318
- By:
- Publication type:
- Article
ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA.
- Published in:
- Neuro-Oncology, 2014, v. 16, n. suppl_3, p. iii44, doi. 10.1093/neuonc/nou209.9
- By:
- Publication type:
- Article
CD19- CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.
- Published in:
- Journal of Cellular & Molecular Medicine, 2016, v. 20, n. 7, p. 1287, doi. 10.1111/jcmm.12810
- By:
- Publication type:
- Article
NK cells engineered to express a GD<sub>2</sub>-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.
- Published in:
- Journal of Cellular & Molecular Medicine, 2012, v. 16, n. 3, p. 569, doi. 10.1111/j.1582-4934.2011.01343.x
- By:
- Publication type:
- Article
Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28-29 2017, Doha, Qatar).
- Published in:
- 2018
- By:
- Publication type:
- research
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Advantages and applications of CAR-expressing natural killer cells.
- Published in:
- Frontiers in Pharmacology, 2015, v. 6, p. 1, doi. 10.3389/fphar.2015.00021
- By:
- Publication type:
- Article
Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo.
- Published in:
- International Journal of Cancer, 2007, v. 120, n. 2, p. 329, doi. 10.1002/ijc.22168
- By:
- Publication type:
- Article
A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma.
- Published in:
- Frontiers in Immunology, 2017, p. 1, doi. 10.3389/fimmu.2017.00676
- By:
- Publication type:
- Article
Chimeric antigen receptor-engineered nK-92 Cells: an off-the-shelf Cellular therapeutic for targeted elimination of Cancer Cells and induction of protective antitumor immunity.
- Published in:
- Frontiers in Immunology, 2017, p. 1, doi. 10.3389/fimmu.2017.00533
- By:
- Publication type:
- Article
Genetically engineered CAR NK cells display selective cytotoxicity against FLT3‐positive B‐ALL and inhibit in vivo leukemia growth.
- Published in:
- International Journal of Cancer, 2019, v. 145, n. 7, p. 1935, doi. 10.1002/ijc.32269
- By:
- Publication type:
- Article
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
- Published in:
- International Journal of Cancer, 2016, v. 139, n. 8, p. 1799, doi. 10.1002/ijc.30217
- By:
- Publication type:
- Article
A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
- Published in:
- International Journal of Cancer, 2014, v. 134, n. 11, p. 2547, doi. 10.1002/ijc.28585
- By:
- Publication type:
- Article
Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression.
- Published in:
- Molecular Therapy, 2009, v. 17, n. 10, p. 1779, doi. 10.1038/mt.2009.133
- By:
- Publication type:
- Article
Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
- Published in:
- Cells (2073-4409), 2024, v. 13, n. 3, p. 246, doi. 10.3390/cells13030246
- By:
- Publication type:
- Article
Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK Cells with Enhanced Antitumor Activity.
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 4, p. 811, doi. 10.3390/cells9040811
- By:
- Publication type:
- Article
Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging.
- Published in:
- Magnetic Resonance in Medicine, 2011, v. 65, n. 3, p. 756, doi. 10.1002/mrm.22652
- By:
- Publication type:
- Article
Bispecific killer cell engagers employing species crossreactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2- positive malignancies.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1457887
- By:
- Publication type:
- Article
Optical Imaging of Cellular Immunotherapy against Prostate Cancer.
- Published in:
- Molecular Imaging, 2009, v. 8, n. 1, p. 15, doi. 10.2310/7290.2009.00002
- By:
- Publication type:
- Article
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article